By: Kairos Ventures On: September 12, 2022 In: Linnaeus, Portfolio News

Linnaeus Therapeutics announced the presentation of clinical biomarker data from its study of LNS8801 as a monotherapy and in...

Read more
By: Kairos Ventures On: June 6, 2022 In: Linnaeus, Portfolio News

Linnaeus Therapeutics, Inc. announced the presentation of clinical data from its phase 1/2 clinical trial of LNS8801 in combination...

Read more
By: Kairos Ventures On: April 11, 2022 In: Linnaeus, Portfolio News

Linnaeus Therapeutics, Inc. announced that the laboratory of Gary Schwartz, MD at Columbia University Irving Medical Center presented new findings...

Read more
By: Charissa On: April 6, 2022 In: Linnaeus, Portfolio News

Linnaeus Therapeutics announced it has been awarded a Phase 2 Bridge Small Business Innovation Research ("SBIR") Award by the...

Read more
By: Kairos Ventures On: June 15, 2021 In: Linnaeus, Portfolio News

Linnaeus Therapeutics announced the expansion of its ongoing clinical collaboration with Merck to include multiple additional phase 2 cohorts....

Read more
By: Kairos Ventures On: June 7, 2021 In: Linnaeus, Portfolio News

Linnaeus Therapeutics, Inc. announced the presentation of clinical data from its phase 1 dose-escalation study of LNS8801 as a...

Read more
By: Kairos Ventures On: March 10, 2021 In: Linnaeus, Portfolio News

Linnaeus Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for LNS8801 for...

Read more
By: Kairos Ventures On: March 3, 2021 In: Linnaeus, Portfolio News

Linnaeus Therapeutics, Inc. announced that on March 2, 2021 the U.S. Patent and Trademark Office issued U.S. patent 10,934,277...

Read more
By: Kairos Ventures On: January 12, 2021 In: Linnaeus, Portfolio News

Launched at Penn’s UPstart incubator, Haddonfield’s Linnaeus Therapeutics is in the early stages of clinical trials for an anti-cancer...

Read more
By: Kairos Ventures On: October 13, 2020 In: Linnaeus, Portfolio News

Linnaeus Therapeutics announced that it has dosed the first patient in its phase 1/2 adaptive-design clinical trial of its...

Read more